Since its formal establishment in 1987, MEBO has developed scientifically revolutionary  medicines and nutrients that have been used successfully to treat millions of patients. In addition to China, MEBO products have been introduced to more than 20 countries, including Singapore, South Korea, the Philippines, Thailand, Malaysia and most of the Middle Eastern countries including United Arab Emirates, Egypt, Saudi Arabia and Kuwait. They are currently being developed for the U.S. market.

SKIN REGENERATION FOR BURNS AND WOUNDS

MEBO’s achievements in the regeneration of human organs began in 1987 with the physiological repair and regeneration of extensively wounded skin, the largest organ of the body, by using a proprietary product called moist-exposed burn ointment (MEBO)  from which the company’s name is originated.  The MEBO wound ointment, used in conjunction with the techniques of Moist-Exposed Burn Treatment (MEBT), have benefited millions—healing acute or chronic wounds  restoring the physiological structure and function of the skin, and dramatically reducing morbidity and mortality of burn patients.

Initial international awareness of MEBO came in the 1990s when the press reported on the MEBO burn treatment that not only saved lives but also prevented significant scarring. On May 7, 1990 Newsweek magazine published an article entitled “A Simpler Way to Save Lives  Could a New Medication from China Change the World’s Approach to Treating Burn Injuries?” CNN also featured Dr. Xu and his treatment of burn patients in 1990

REGENERATION BEYOND THE SKIN

MEBO’s medicines and nutrients are combinations of essential natural substances processed through and formulated with our proprietary technologies. Moving beyond a well-established clinical and scientific foundation based in burn treatment, acute and chronic wound healing, and the repair and regeneration of the gastrointestinal tract lining, MEBO is now exploring new medicines and nutrients using MEBO’s groundbreaking regenerative approaches.  MEBO is researching applications for a wide range of health concerns  — from cancers, blood disorders, neurodegenerative diseases and diabetes, to other diseases associated with organ degeneration and failure.

In the application of MEBO products to cellular, animal and clinical models for organ injury and diseases, we discovered over time that human somatic cells can be activated or induced to function much like stem cells, to proliferate and differentiate appropriately in particular organs in the body.  This can occur if they have the appropriate environment and nutritional setting to help replenish, repair and regenerate tissues and organs that are injured, degenerated, aged or diseased.  In animal and human studies already completed or currently underway, remarkable and sometimes surprising results have been achieved and are now being pursued to establish the clinical evidence and understand the science behind the regenerative process that does not rely on tissue/organ transplantation.

MEBO’s mission is to continue to harness the natural power of the human body to regenerate or heal itself by developing additional MEBO regenerative medicines and nutrients that will significantly impact human health.  If successful, it is believed that these new technologies and approaches may help prevent and treat diseases associated with premature aging, organ failure, or cancerous transformation of normal cells.